Zymeworks: Citi Flags Major Upside Catalyst Ahead of August 25 FDA Decision
Citi places Zymeworks on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA.
/ 8 items
#ZYME↓
Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.
Ziihera GEA Trial: Modest Gains Come With Severe Side Effects
Jazz new stomach cancer drug extends survival by 7 months but causes severe side effects in 25% of patients. Ziihera-only combination failed to achieve statistical significance for overall survival at first analysis.
Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.